USP releases compendium of quality standards for compounded medicines.
The United States Pharmacopeia Convention (USP) has published the USP Compounding Compendium to provide easy access to quality related standards for compounded medicines. The compendium gives compounding practitioners access to all compounding-related general chapters from the United States Pharmacopeia–National Formulary (USP–NF) and features more than 40 supporting general chapters and more than 170 compounding preparation monographs. It also includes the USP–NF General Notices and Requirements, “which provide definitions and important information necessary to correctly interpret and apply compounding standards.”
“USP has a deep historic connection to the practice of pharmacy, stretching back to the very beginning of our origination nearly 200 years ago when practitioners regularly prepared medicines as-needed,” noted USP Chief Executive Officer Ronald T. Piervincenzi, PhD, in a press release. “Our founders, most of whom practiced and taught medicine and/or pharmacy, promoted quality standards as a tool to advance their profession and improve public health, and USP’s commitment to those core ideals continues today.”
The USP Compounding Compendium will be updated with the release of each new USP–NF edition and supplement. Subscribers can access and download all updates during their 12-month subscription period. USP has partnered with the International Academy of Compounding Pharmacists (IACP) and the National Community Pharmacy Association (NCPA) to enable their members to purchase the USP Compounding Compendium directly through the IACP and NCPA websites.
Source: USP.org
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.